Phase 2 trial in 272 pregnant women: two doses of GBS-AlpN group B streptococcus vaccine gave 67-94% of infants cord IgG above 1.0 μg/mL vs none with placebo; one dose gave lower levels. Nine infant deaths occurred, none judged vaccine-related.
RCTn = 272
Heath et al. Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study